Preoperative chemotherapy for stage IIIA non-small cell lung cancer

Current Opinion in Oncology

Volumn 9, Issue 2, 1997, Pages 149-155

  Rosell, Rafael ^a   López Cabrerizo, Maria Paz ^a   Astudillo, Julio ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; INTERFERON; MITOMYCIN; VINBLASTINE; VINCRISTINE;

CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; HUMAN; LUNG NON SMALL CELL CANCER; MULTIMODALITY CANCER THERAPY; PATIENT SELECTION; POSITRON EMISSION TOMOGRAPHY; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; REVIEW;

EID: 8244259176     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-199703000-00008     Document Type: Review

References (48)

1. Bülzebruck H, Bopp R, Drings P, Bauer E, Krysa S, Probst G, van Kaick G, Müller K-M, Vogt-Moykopf I: New aspects in the staging of lung cancer: prospective validation of the International Union against Cancer TNM classification. Cancer 1992, 70:1102-1110.
2. Goldstraw P, Pastorino U: The messages from recently completed surgical trials on lung cancer. Eur J Surg Oncol 1996, 22:1-4.
3. Edelman MJ, Gandara DR, Roach M III, Benfield JR: Multimodality therapy in stage III non-small cell lung cancer. Ann Thorac Surg 1996, 61:1564-1572 An updated analysis of the database of operative and nonoperative approaches for patients with stage III non-small cell lung cancer is used to compare response rates, resectability, and long-term survival.
4. Rusch VW: Resection of stage III non-small cell lung cancer following induction therapy. World J Surg 1995, 19:817-822. The author describes the background of preoperative chemotherapy and revises major principles of the surgical management of patients undergoing this procedure.
5. Rosell R, Font A, Pifarré A, Canela M, Maurel J, Arellano A, Izquierdo J: The role of induction (neoadjuvant) chemotherapy in stage IIIA NSCLC. Chest 1996, 109:102S-106S.
6. Buccheri G: Is there a standard treatment for locally advanced non-small cell lung cancer? Chest 1996, 109:864-866
7. Milroy R, Macbeth F: Neoadjuvant chemotherapy in stage IIIa non-small cell lung cancer. Thorax 1995, 50(suppl 1):S25-S30.
8. Johnson DH, Turrisi A, Pass HI: Combined-modality treatment for locally advanced non-small cell lung cancer. In Lung Cancer: Principles and Practice. Edited by Pass HI, Mitchell JB, Johnson DH, Turrisi AT. Philadelphia: Lippincott-Raven; 1996:863-873. A detailed, comprehensive, and up-to-date overview of the role of preoperative chemotherapy extensively referenced.
9. Rosell R, Gómez-Codina J, Camps C, Maestre J, Padilla J, Canto A, Mate JL, Li S, Roig J, Olazábal A, Canela M, Ariza A, Skacel Z, Morera-Prat J, Abad A: A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl J Med 1994, 330:153-158.
10. Roth JA, Fossella F, Komaki R, Ryan B, Putnam JB Jr, Lee JS, Dhingra H, De Caro L, Chasen M, McGavran M, Atkinson EN, Hong WK: A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. J Natl Cancer Inst 1994, 86:673-680.
11. Pass HI, Pogrebniak HW, Steinberg SM, Mulshine J, Minna J: Randomized trial of neoadjuvant therapy for lung cancer: interim analysis. Ann Thorac Surg 1992, 53:992-998.
12. Non-Small Cell Lung Cancer Collaborative Group: Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Br Med J 1995, 311:899-909. The Non-Small Cell Lung Cancer Collaborative Group registry database of more than 9387 patients established the benefit of cisplatin-containing regimens in different subsets of patients in trials comparing surgery with surgery plus chemotherapy, trials comparing radiotherapy with radiotherapy plus chemotherapy, and in trials comparing supportive care with chemotherapy.
13. Brundage MD, Mackillop WJ: Locally advanced non-small cell lung cancer: do we know the questions?: a survey of randomized trials from 1966-1993. J Clin Epidemiol 1996, 49:183-192. The paper reports an accurate review of the methodological flaws in randomized trials, especially in chemoradiotherapy studies, and it stresses the relevance of unifying outcome parameters. Although what should be the endpoints of trials is elegantly discussed, the reader can not expect to find useful issues concerning the role of preoperative chemotherapy or surgical aspects.
14. Rusch V, Klimstra D, Venkatraman E, Oliver J, Martini N, Gralla R, Kris M, Dmitrovsky E: Aberrant p53 expression predicts clinical resistance to cisplatin-based chemotherapy in locally advanced non-small cell lung cancer. Cancer Res 1995, 55:5038-5042. The paper reports that high levels of p53 staining elicited a lack of response to preoperative chemotherapy as assessed by pathologic response in a retrieval analysis from 52 of 82 stage IIIA patients who underwent resection.
15. Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other diseases. Nature Med 1995, 1:27-31.
16. Folkman J: Clinical applications of research on angiogenesis. N Engl J Med 1995, 333:1757-1763.
17. Belotti D, Nicoletti L, Vergani V, Rieppi M, Drudis T, Viale G, Giavazzi R, Taraboletti G: Paclitaxel (Taxol), a microtubule affecting drug, inhibits tumor induced angiogenesis [abstract]. Proc Am Assoc Cancer Res 1996, 37:57.
18. Mathisen DJ, Wain JC, Wright C, Choi N, Carey R, Hilgenberg A, Grossbard M, Lynch T, Grillo H: Assessment of preoperative accelerated radiotherapy and chemotherapy in stage IIIA (N2) non-small-cell lung cancer. J Thorac Cardiovasc Surg 1996, 111:123-133. This is an excellent phase II study of multimodality treatment in mediastinoscopically proven N2 involvement, and it highlights the relevance of downstaging N2 disease as a useful surrogate for long-term survival.
19. Milstein D, Kuten A, Saute M, Best LA, Daoud K, Zen-Al-Deen I, Dale J, Robinson E, Preoperative concurrent chemoradiotherapy for unresectable stage III non-small cell lung cancer. Int J Radiat Oncol Biol Phys 1996, 34:1125-1132. A phase II study of preoperative chemoradiation in 36 patients, including stage IIIA and IIIB. The response rates achieved are similar to those of other studies. The study reports a significant proportion of patients downstaged after surgical-pathologic examination.
20. Reboul F, Brewer Y, Vincent P, Chauvet B, Faure CF, Taulelle M: Concurrent cisplatin, etoposide, and radiotherapy for unresectable stage III non-small cell lung cancer: a phase II study. Int J Radiat Oncol Biol Phys 1996, 35:343-350. This paper demonstrates a significant 3-year survival rate: 34.7% in a group of 50 stage-IIIA/B patients who received concurrent cisplatin plus etoposide chemotherapy and irradiation. The authors highlight a significantly better survival for a subset of patients who underwent salvage surgery with a 77.8% 2-year survival rate as compared with 31.2 % for the remainder.
21. Takita H, Blumenson LE, Raghavan D: Neoadjuvant chemotherapy of stage IIIA and B lung carcinoma using the PACCO regimen. J Surg Oncol 1995, 59:147-150.
22. Chella A, Lucchi M, Ribechini A, Silvano G, Mussi A, Janni A, Angeletti CA: Pre-operative chemotherapy for stage IIIa (N2) non-small cell lung cancer. Eur J Surg Oncol 1995, 21:393-397.
23. Ciriaco P, Rendina EA, Venuta F, De Giacomo T, Della Rocca G, Flaishman I, Baroni C, Cortesi E, Bonsignore G, Ricci C: Preoperative chemotherapy and immunochemotherapy for locally advanced stage IIIA and IIIB non-small cell lung cancer. Eur J Cardio Thorac Surg 1995, 9:305-309.
24. Sugarbaker DJ, Herndon J, Kohman LJ, Krasna MJ, Green MR: Results of Cancer and Leukemia Group B protocol 8935: a multiinstitutional phase II trimodality trial for stage IIIA(N2) non-small-cell lung cancer. J Thorac Cardiovasc Surg 1995, 109:473-485. A very good phase II study of cisplatin and vinblastine preoperative chemotherapy in 74 mediastmoscopically confirmed N2 patients, followed by surgical resection and radical lymphadenectomy and postthoractomy irradiation. This paper underlines a significant 46% 3-year survival rate for patients with complete resection.
25. Martini N, Kris MG, Flehinger BJ, Gralla RJ, Bains MS. Burt ME, Heelan R, Mc Cormack PM, Pisters KMW, Rigas JR, et al.: Preoperative chemotherapy for stage IIIa (N2) lung cancer: the Sloan-Kettering experience with 136 patients. Ann Thorac Surg 1993, 55:1365-1374.
26. Fossella FV, Rivera E, Roth JA: Preoperative chemotherapy for stage IIIA non-small cell lung cancer. Curr Opin Oncol 1996, 8:106-111.
27. Albain KS, Rusch VW, Crowley JJ, Rice TW, Turrisi AT, Weick JK, Lonchyna VA, Presant CA, McKenna RJ, Gandara DR, et al.: Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stage IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805. J Clin Oncol 1995, 13:1880-1892.
28. Izbicki JR, Passlick B, Karg O, Bloeche C, Pantel K, Knoefel WT, Thetter O: Impact of radical systematic mediastinal lymphadenectomy on tumor staging in lung cancer. Ann Thorac Surg 1995, 59:209-214. An excellent article on the value of radical lymphadenectomy in the prognosis of patients with N2 disease.
29. 131I-labeled epidermal growth factor. Clin Cancer Res 1996, 2:13-20.
30. Wahl RL, Quint LE, Greenough RL, Meyer CR, White RJ, Orringer MB: Staging of mediastinal non-small cell lung cancer with FDG PET, CT, and fusion images: preliminary prospective evaluation. Radiology 1994, 191:371-377.
31. Chin R, Ward R, Keyes JW, Choplin RH, Reed JC, Wallenhaupt S, Hudspeth AS, Haponik EF: Mediastinal staging of non-small-cell lung cancer with positron emission tomography. Am J Respir Crit Care Med 1995, 152:2090-2096.
32. Duhaylongsod FG, Lowe VJ, Patz EF, Vaughn Al, Coleman RE, Wolfe WG: Detection of primary and recurrent lung cancer by means of F-18 fluorodeoxyglucose positron emission tomography (FDG PET). J Thorac Cardiovasc Surg 1995, 110:130-140.
33. Frank A, Lefkowitz D, Jaeger S, Gobar L, Sunderland J, Gupta N, Scott W, Mailliard J, Lynch H, Bishop J, Thorpe P, Dewan N: Decision logic for retreatment of asymptomatic lung cancer recurrence based on positron emission tomography findings. Int J Radiat Oncol Biol Phys 1995, 32:1495-1512. An excellent paper on the comparison of CT scan and FDG PET in the investigation of early relapse in lung cancer patients.
34. Nishio M, Koshikawa T, Kuroishi T, Suyama M, Uchida K, Takagi Y, Washimi O, Sugiura T, Ariyoshi Y, Takahashi T, et al.: Prognostic significance of abnormal p53 accumulation in primary, resected non-small-cell lung cancers. J Clin Oncol 1996, 14:497-502.
35. Rosell R, Monzo M, Pifarré A, Ariza A, Sánchez JJ, Moreno I, Maurel J, López MP, Abad A, de Anta JM: Molecular staging of non-small cell lung cancer according to K-ras genotypes. Clin Cancer Res 1996, 2:1083-1086.
36. Angelatti CA, Lucchi M, Fontanini M, Mussi A, Chella A, Ribechini A, Vignati S, Bevilacqua G: Prognostic significance of tumoral angiogenesis in completely resected late stage lung carcinoma (stage IIIA-N2). Cancer 1996, 78:409-415. This is a study of neovascularization estimated by microvessel count performed on 96 stage III NSCLC resected tumors. This study provided data indicating that neovascularization can predict metastatic disease.
37. Hung J, Kishimoto Y, Sugio K, Virmani A, Mcintire DD, Minna JD, Gazdar AF: Allele-specific chromosome 3p deletions occur at an early stage in the pathogenesis of lung carcinoma. JAMA 1995, 273:558-563.
38. Thiberville L, Bourguignon J, Metayer J, Bost F, Diarra-Mehrpour M, Bignon J, Lam S, Martin J-P, Nouvet G: Frequency and prognostic evaluation of 3p21-22 allelic losses in non-small-cell lung cancer. Int J Cancer (Pred Oncol) 1995, 64:371-377.
39. Mitsudomi T, Oyama T, Nishida K, Ogami A, Osaki T, Sugio K, Yasumoto K, Sugimachi K, Gazdar AF: Loss of heterozygosity at 3p in non-small cell lung cancer and its prognostic implication. Clin Cancer Res 1996, 2:1185-1189.
40. Ryberg D, Lindstedt BA, Zienolddiny S, Haugen A: A hereditary genetic marker closely associated with microsatellite instability in lung cancer. Cancer Res 1995, 55:3996-3999.
41. Adachi J-I, Shiseki M, Okazaki T, Ishimaru G, Noguchi M, Hirohashi S, Yokota J: Microsatellite instability in primary and metastatic lung carcinomas. Genes Chromosom Cancer 1995, 14:301-306.
42. Miozzo M, Sozzi G, Musso K, Pilotti S, Incarbone M, Pastorino U, Pierotti MA: Microsatellite alterations in bronchial and sputum specimens of lung cancer patients. Cancer Res 1996, 56:2285-2288.
43. Gazdar AF, Virmani AK, Hung J, Fong K, Minna JD: Microsatellite alterations in human lung cancer cell lines [abstract]. Proc Am Assoc Cancer Res 1996, 37:543.
44. Pifarré A, Rosell R, Monzó M, De Anta JM, Moreno I, Sánchez JJ, Ariza A, Mate JL, Martinez E, Sánchez M: Prognostic value of replication errors on chromosomes 2p and 3p in non-small lung cancer. Br J Cancer 1997, 75:184-185.
45. Rosell R, Pifarré A, Monzó M, Astudillo J, López-Cabrerizo MP, Calvo R, Moreno I, Sánchez-Céspedes M, Font A, Navas-Palacios JJ: Reduced survival in patients with stage 1 non-small cell lung cancer associated with DNA replication errors. Int J Cancer 1997, in press.
46. Giaccone G, Tonato M: Ongoing clinical trials in lung cancer. Eur J Surg Oncol 1996, 22:4-9.
47. Lee JS, Scott C, Komaki R, Fossella FV, Dundas GS, McDonald S, Byhardt RW, Curran WJ Jr: Concurrent chemoradiation therapy with oral etoposide and cisplatin for locally advanced inoperable non-small-cell lung cancer: Radiation Therapy Oncology Group protocol 91-06. J Clin Oncol 1996, 14:1055-1064. A relevant phase II study that shows the beneficial effect of concurrent chemoradiation with oral etoposide and cisplatin in stage IIIA/IIIB NSCLC patients, with 18.9 overall median survival time and 35% 2-year survival rate.
48. Le Péchoux C, Arriagada R, Le Chevalier T, Bretel J-J, Cosset BP, Ruffié P, Baldeyrou P, Grunenwald D: Concurrent cisplatin-vindesine and hyperfractionated thoracic radiotherapy in locally advanced non-small cell lung cancer, Int J Radiat Oncol Biol Phys 1996, 35:519-525. A particularly encouraging small series of 34 stage-IIIA/IIIB patients who were treated with concurrent cisplatin plus vindesine chemotherapy and hyperfractionated thoracic irradiation (60 Gy with two daily sessions of 125 cGy) followed by two high-dose cisplatin chemotherapy cycles. However, the 33% 2-year survival rate dropped to 12% at 3 years.